The largest database of trusted experimental protocols

W 54011

Manufactured by Merck Group
Sourced in Germany

The W-54011 is a laboratory centrifuge produced by Merck Group. It is designed to separate and isolate materials of different densities through the application of centrifugal force. The device features a compact design and is suitable for various applications in scientific research and testing environments.

Automatically generated - may contain errors

4 protocols using w 54011

1

In vivo and ex vivo C5aR1 blockade

Check if the same lab product or an alternative is used in the 5 most similar protocols
For in vivo blockade of mouse C5aR1, cyclic peptide PMX205 was used as outlined above. Synthesis of PMX205 (cyclic hexapeptide hydro-cinnamate-[l-ornithine-proline-d-cyclohexylalanine-tryptophan-arginine]) is described elsewhere (62 (link)). For ex vivo blockade of human C5aR1, cyclic peptide PMX53 (Tocris Bioscience) and nonpeptide compound W-54011 (Merck Millipore) were used at the indicated concentrations.
+ Open protocol
+ Expand
2

Inhibiting PMN-mediated HIV-1 inactivation

Check if the same lab product or an alternative is used in the 5 most similar protocols
2x106 mock or X4 HIV-1 infected HLACs were co-cultured with 1x106 PMNs in the presence of the indicated PMN inhibitors: 5U/ml rDNase I (Sigma-Aldrich), 1000U/ml Catalase (Sigma-Aldrich), 100μM 4-aminobenzoic acid hydrazide (4-ABAH; Santa Cruz), 50μM 4-(2-aminoethyl) benzenesulfonylfluoride (AEBSF; ThermoFisher), 1μM iODN 2088 (Enzo Life Sciences), and 300μM W-54011 (Merck). PMNs were pre-incubated with 100μg/ml blocking antibodies against CD18 (Clone TS1/18), CD11b (Clone ICRF44) and CD11a (Clone HI111) for 30min at room temperature. Viral titers were determined by SG-PERT similar to co-cultures in the absence of inhibitors.
+ Open protocol
+ Expand
3

Complement Inhibition and Thromboelastography

Check if the same lab product or an alternative is used in the 5 most similar protocols
Changes in TEG were evaluated following complement inhibition. Two receptor inhibitors were used, one for the C3a receptor (SB 290157, C3aRI, Cayman Chemical Company, Ann Arbor, MI) and another for the C5a receptor (W54011, C5aRI, EMD Millipore, Billerica, MA).(32 (link), 33 (link)) The C3aRI and C5aRI were solubilized in dimethyl sulfoxide (DMSO) and further diluted in phosphate-buffered saline (PBS) to obtain the experimental solution per supplier instructions. An equivalent carrier (0.05% v/v DMSO in PBS) was used as a control. The C3aRI and C5aRI inhibitors were added to 500 μL of whole blood (WB) for a final concentration of 300 nM and 6 nM, respectively. These doses are comparable to the inhibitors’ respective IC50 doses of the C3aRI (IC50 of 200 nM) and C5aRI (IC50 of 3.1 nM), respectively. (32 (link), 33 (link)) To evaluate inhibition of upstream alternative complement pathway, the C3 and C3b inhibitor Compstatin (Tocris Bioscience, Bristol, UK) was added to whole blood to a final concentration of 25 μM and 50 μM. After the addition of inhibitors, samples were incubated for five minutes in 37°C water bath prior to running TEG using the same methodology as described previously.
+ Open protocol
+ Expand
4

C5a/C5aR Binding and Phosphorylation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
MSCs were seeded overnight at (3000 cells/cm 2 ) in 96-well microplates. Cells were incubated with conditioned media for 5 min. In parallel, cells were also pre-incubated for 5 min with or without 10 nM of W54011, a specific C5aR antagonist (Merck, Darmstadt, Germany). After washing, cells were fixed (3% paraformaldehyde, 20 min) and saturated (5% BSA, 1 h). C5a/C5aR binding was visualized by biotinylated mouse anti-human C5a Supernatants from injured PDL cells incubated with materials' extracts (conditioned media) were applied on MSCs cultures to evaluate C5a binding to MSCs C5aR and its phosphorylation by ELISA, to quantify their proliferation using MTT assay and their migration using Boyden chambers IgG (2 μg/mL, 2 h) followed by Streptavidin-HRP (20 min) and substrate solution (20 min) (R&D Systems, Lille, France). C5aR phosphorylation was visualized by biotinylated rabbit antihuman C5aR-p(Ser338) (Abcam, Paris France) (2 μg/mL, 2 h) followed by Streptavidin-HRP (20 min) and substrate solution (20 min) (R&D Systems, Lille, France). Optical densities were measured at 650 nm using an automatic microplate spectrophotometer (Metertech Inc., Taipei, Taiwan). C5a/C5aR binding and C5aR phosphorylation are expressed as percentage of the control condition.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!